Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy.

RNA interference (RNAi) is triggered by oligonucleotides that are about 21-23 nucleotides long and are capable of inducing the destruction of complementary mRNA. The RNAi technique has been successfully utilized to target HIV replication; however, the main limitation to the successful utilization of this technique in vivo is the inability of naked siRNA to cross the cell membrane by diffusion due to its strong anionic charge and large molecular weight. This review describes current nonviral nanotechnological approaches to deliver anti-HIV siRNAs for the treatment of HIV infection.

[1]  S. Adesina,et al.  The effect of formulation variables on drug loading of antitubercular drugs in nanoparticle formulations , 2015 .

[2]  Jijin Gu,et al.  Biodegradable Film for the Targeted Delivery of siRNA-Loaded Nanoparticles to Vaginal Immune Cells. , 2015, Molecular pharmaceutics.

[3]  Yihui Deng,et al.  A review on phospholipids and their main applications in drug delivery systems , 2015 .

[4]  K. Morris,et al.  Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. , 2015, Chemistry & biology.

[5]  S. Álvarez,et al.  In vivo delivery of siRNA to the brain by carbosilane dendrimer. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[6]  S. Adesina,et al.  Optimization of the fabrication of novel stealth PLA-based nanoparticles by dispersion polymerization using D-optimal mixture design , 2014, Drug development and industrial pharmacy.

[7]  J. Rossi,et al.  Cell-Type–Specific Aptamer and Aptamer-Small Interfering RNA Conjugates for Targeted Human Immunodeficiency Virus Type 1 Therapy , 2014, Journal of Investigative Medicine.

[8]  Di Chen,et al.  Single-walled carbon nanotubes noncovalently functionalized with lipid modified polyethylenimine for siRNA delivery in vitro and in vivo. , 2014, Bioconjugate chemistry.

[9]  Viney Lather,et al.  Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues , 2014, Journal of pharmacy & bioallied sciences.

[10]  C. Liu,et al.  Structurally flexible triethanolamine-core poly(amidoamine) dendrimers as effective nanovectors to deliver RNAi-based therapeutics. , 2014, Biotechnology advances.

[11]  Shutao Guo,et al.  Nanoparticles containing insoluble drug for cancer therapy. , 2014, Biotechnology advances.

[12]  Á. Corbí,et al.  Carbosilane dendrimers as gene delivery agents for the treatment of HIV infection. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[13]  F. Chen,et al.  Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers and Viral Infections , 2014, Theranostics.

[14]  Sung Tae Kim,et al.  Gold nanoparticles for nucleic acid delivery. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  Solmaz Maleki Dizaj,et al.  A sight on the current nanoparticle-based gene delivery vectors , 2014, Nanoscale Research Letters.

[16]  F. Albericio,et al.  Amphiphilic cationic carbosilane-PEG dendrimers: synthesis and applications in gene therapy. , 2014, European journal of medicinal chemistry.

[17]  B. Yavuz,et al.  Dendrimeric Systems and Their Applications in Ocular Drug Delivery , 2013, TheScientificWorldJournal.

[18]  Dominika Wrobel,et al.  Interaction of cationic carbosilane dendrimers and their complexes with siRNA with erythrocytes and red blood cell ghosts , 2013, Biochimica et Biophysica Acta (BBA) - Biomembranes.

[19]  S. Gambhir,et al.  Nanooncology: The future of cancer diagnosis and therapy , 2013, CA: a cancer journal for clinicians.

[20]  Young-Seok Cho,et al.  Recent Developments in Nanoparticle-Based siRNA Delivery for Cancer Therapy , 2013, BioMed research international.

[21]  A. Kell,et al.  Influence of lipoplex surface charge on siRNA delivery: application to the in vitro downregulation of CXCR4 HIV-1 co-receptor , 2013, Expert opinion on biological therapy.

[22]  Soodabeh Davaran,et al.  Liposome: classification, preparation, and applications , 2013, Nanoscale Research Letters.

[23]  J. Rossi,et al.  Functional In Vivo Delivery of Multiplexed Anti-HIV-1 siRNAs via a Chemically Synthesized Aptamer With a Sticky Bridge , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  N. Jawahar,et al.  Polymeric nanoparticles for drug delivery and targeting: A comprehensive review , 2012 .

[25]  A. Caminade,et al.  Validation of a generation 4 phosphorus-containing polycationic dendrimer for gene delivery against HIV-1. , 2012, Current medicinal chemistry.

[26]  T. Hianik,et al.  siRNA carriers based on carbosilane dendrimers affect zeta potential and size of phospholipid vesicles. , 2012, Biochimica et biophysica acta.

[27]  Yan Li,et al.  Quantum Dots for Cancer Research: Current Status, Remaining Issues, and Future Perspectives , 2012, Cancer biology & medicine.

[28]  H. Car,et al.  Nanoparticles as drug delivery systems , 2012, Pharmacological reports : PR.

[29]  Yunfeng Lu,et al.  Single siRNA nanocapsules for enhanced RNAi delivery. , 2012, Journal of the American Chemical Society.

[30]  Nouri Nayerossadat,et al.  Viral and nonviral delivery systems for gene delivery , 2012, Advanced biomedical research.

[31]  W. Law,et al.  Nanoparticle Based Galectin-1 Gene Silencing, Implications in Methamphetamine Regulation of HIV-1 Infection in Monocyte Derived Macrophages , 2012, Journal of Neuroimmune Pharmacology.

[32]  R. Weisman,et al.  Carbon Nanotubes: Solution for the Therapeutic Delivery of siRNA? , 2012, Materials.

[33]  T. Kissel,et al.  PEGylated poly(ethylene imine) copolymer-delivered siRNA inhibits HIV replication in vitro. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[34]  Ling Peng,et al.  Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  Anil Mahapatro,et al.  Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines , 2011, Journal of nanobiotechnology.

[36]  Wim E Hennink,et al.  SiRNA delivery with functionalized carbon nanotubes. , 2011, International journal of pharmaceutics.

[37]  S. Eszterhas,et al.  Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants , 2011, Infectious disease reports.

[38]  J. Rossi,et al.  Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery. , 2011, Journal of visualized experiments : JoVE.

[39]  David D. Smith,et al.  Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. , 2011, Methods.

[40]  W. Law,et al.  Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA , 2011, Pathology research international.

[41]  P. Ortega,et al.  Carbosilane dendrimers NN8 and NN16 form a stable complex with siGAG1. , 2011, Colloids and surfaces. B, Biointerfaces.

[42]  Jerry C. Chang,et al.  Biocompatible quantum dots for biological applications. , 2011, Chemistry & biology.

[43]  J. Rossi,et al.  An Aptamer-siRNA Chimera Suppresses HIV-1 Viral Loads and Protects from Helper CD4+ T Cell Decline in Humanized Mice , 2011, Science Translational Medicine.

[44]  P. Ortega,et al.  Carbosilane Dendrimers to Transfect Human Astrocytes with Small Interfering RNA Targeting Human Immunodeficiency Virus , 2010, BioDrugs.

[45]  L. Rohan,et al.  Progress in antiretroviral drug delivery using nanotechnology , 2010, International journal of nanomedicine.

[46]  J. Au,et al.  Delivery of siRNA Therapeutics: Barriers and Carriers , 2010, The AAPS Journal.

[47]  M. J. Serramía,et al.  Gene Therapy in HIV‐Infected Cells to Decrease Viral Impact by Using an Alternative Delivery Method , 2010, ChemMedChem.

[48]  Gang Wang,et al.  A novel poly(l-glutamic acid) dendrimer based drug delivery system with both pH-sensitive and targeting functions. , 2010, Molecular pharmaceutics.

[49]  B. Sarmento,et al.  Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. , 2010, Advanced drug delivery reviews.

[50]  F. Kirchhoff,et al.  Host proteins involved in HIV infection: new therapeutic targets. , 2010, Biochimica et biophysica acta.

[51]  R. Langer,et al.  Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. , 2010, Nanomedicine.

[52]  D. Peer,et al.  RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  Jin-Zhi Du,et al.  Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. , 2010, Small.

[54]  Xiang Gao,et al.  Nonviral Gene Delivery: Principle, Limitations, and Recent Progress , 2009, The AAPS Journal.

[55]  B. Nanjwade,et al.  Dendrimers: emerging polymers for drug-delivery systems. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[56]  V. Labhasetwar,et al.  Targeting anti-HIV drugs to the CNS , 2009, Expert opinion on drug delivery.

[57]  Christine Vauthier,et al.  Methods for the Preparation and Manufacture of Polymeric Nanoparticles , 2009, Pharmaceutical Research.

[58]  Sung Wan Kim,et al.  Efficient siRNA Delivery with Non-viral Polymeric Vehicles , 2009, Pharmaceutical Research.

[59]  E. Simanek,et al.  Nonviral vectors for gene delivery. , 2009, Chemical reviews.

[60]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[61]  H. Dai,et al.  Carbon nanotubes in biology and medicine: In vitro and in vivo detection, imaging and drug delivery , 2009, Nano research.

[62]  P. Ortega,et al.  Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[63]  Tae Gwan Park,et al.  Amine-functionalized gold nanoparticles as non-cytotoxic and efficient intracellular siRNA delivery carriers. , 2008, International journal of pharmaceutics.

[64]  Dale L. Greiner,et al.  T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice , 2008, Cell.

[65]  John J Rossi,et al.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[66]  Shuming Nie,et al.  Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. , 2008, Journal of the American Chemical Society.

[67]  Matthias Epple,et al.  Inorganic nanoparticles as carriers of nucleic acids into cells. , 2008, Angewandte Chemie.

[68]  Barbara Ruozi,et al.  Polymeric nanoparticles for the drug delivery to the central nervous system , 2008, Expert opinion on drug delivery.

[69]  S. Parveen,et al.  Polymeric nanoparticles for cancer therapy , 2008, Journal of drug targeting.

[70]  N. K. Jain,et al.  Long circulating PEGylated poly(d,l-lactide-co-glycolide) nanoparticulate delivery of Docetaxel to solid tumors , 2008 .

[71]  Yuki Naito,et al.  Optimal design and validation of antiviral siRNA for targeting HIV-1 , 2007, Retrovirology.

[72]  Steven C Kazmierczak,et al.  From diagnostics to therapy: prospects of quantum dots. , 2007, Clinical biochemistry.

[73]  C. Laurencin,et al.  Biodegradable polymers as biomaterials , 2007 .

[74]  Erkki Ruoslahti,et al.  Targeted quantum dot conjugates for siRNA delivery. , 2007, Bioconjugate chemistry.

[75]  M. S. Muthu,et al.  Preparation and characterization of nanoparticles containing an atypical antipsychotic agent. , 2007, Nanomedicine.

[76]  Hongjie Dai,et al.  siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. , 2007, Angewandte Chemie.

[77]  A. Kenwright,et al.  Synthesis, Characterization, and Hydrolytic Degradation of Polylactide-Functionalized Polyoxanorbornenes , 2007 .

[78]  K. Avgoustakis,et al.  Effect of Conditions of Preparation on the Size and Encapsulation Properties of PLGA-mPEG Nanoparticles of Cisplatin , 2007, Drug delivery.

[79]  P. Couvreur,et al.  Nanotechnology: Intelligent Design to Treat Complex Disease , 2006, Pharmaceutical Research.

[80]  M. Radosz,et al.  Highly stable core-surface-crosslinked nanoparticles as cisplatin carriers for cancer chemotherapy. , 2006, Colloids and surfaces. B, Biointerfaces.

[81]  Mansoor M Amiji,et al.  Multi-functional polymeric nanoparticles for tumour-targeted drug delivery , 2006, Expert opinion on drug delivery.

[82]  C. Iojoiu,et al.  Synthesis of oligocaprolactone vinyl ether macromonomers and their use for indomethacin encapsulation in polymer nanoparticles based on polycaprolactone macromonomer–maleic anhydride–N‐vinyl pyrrolidone terpolymers , 2006 .

[83]  A. Schätzlein,et al.  Dendrimers in gene delivery. , 2005, Advanced drug delivery reviews.

[84]  Jong-sang Park,et al.  Preparation and characterization of biodegradable nanoparticles entrapping immunodominant peptide conjugated with PEG for oral tolerance induction. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[85]  J. Rossi.  Receptor-targeted siRNAs , 2005, Nature Biotechnology.

[86]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[87]  Yue Zhao,et al.  Formation and degradation of poly(D,L-lactide) nanoparticles and their potential application as controllable releasing devices. , 2004, Macromolecular bioscience.

[88]  K. Lundstrom,et al.  Viral and Non-viral Vectors in Gene Therapy: Technology Development and Clinical Trials , 2003, Technology in cancer research & treatment.

[89]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[90]  R. Taylor,et al.  Design of naltrexone-loaded hydrolyzable crosslinked nanoparticles. , 2002, International journal of pharmaceutics.

[91]  Weijun Luo,et al.  Synthesis and characterization of poly(L‐lactide)‐poly(ethylene glycol) multiblock copolymers , 2002 .

[92]  N Hussain,et al.  Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. , 2001, Advanced drug delivery reviews.

[93]  A. R. Kulkarni,et al.  Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[94]  Stefaan C. De Smedt,et al.  Cationic Polymer Based Gene Delivery Systems , 2000, Pharmaceutical Research.

[95]  X. Deng,et al.  Preparation of biodegradable polylactide-co-poly(ethylene glycol) copolymer by lactide reacted poly(ethylene glycol) , 1999 .

[96]  M. Kiremitçi-Gümüşderelioğlu,et al.  Synthesis, Characterization and in Vitro Degradation of Poly(DL-Lactide)/Poly(DL-Lactide-co-Glycolide) Films , 1999 .

[97]  E. Freed,et al.  HIV-1 gag proteins: diverse functions in the virus life cycle. , 1998, Virology.

[98]  C. M. Agrawal,et al.  Orthopaedic applications for PLA-PGA biodegradable polymers. , 1998, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association.

[99]  Chong-Su Cho,et al.  METHOXY POLY(ETHYLENE GLYCOL) AND CAPROLACTONE AMPHIPHILIC BLOCK CO POLYMERIC MICELLE CONTAINING INDOMETHACIN. II: MICELLE FORMATION AND DRUG RELEASE BEHAVIORS , 1998 .

[100]  Amarnath Sharma,et al.  Liposomes in drug delivery: Progress and limitations , 1997 .

[101]  R. Müller,et al.  The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. , 1995, Advanced drug delivery reviews.

[102]  S. Davis,et al.  Zero order release of protein from poly(d,l-lactide-co-glycolide) microparticles prepared using a modified phase separation technique , 1995 .

[103]  R. Langer.  Polymer-controlled drug delivery systems , 1993 .

[104]  R. Arshady,et al.  Suspension, emulsion, and dispersion polymerization: A methodological survey , 1992 .

[105]  N. Peppas,et al.  Present and future applications of biomaterials in controlled drug delivery systems. , 1981, Biomaterials.

[106]  Hanne Mørck Nielsen,et al.  High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[107]  E. Freed,et al.  Novel approaches to inhibiting HIV-1 replication. , 2010, Antiviral research.

[108]  T. Xu,et al.  Dendrimers as drug carriers: applications in different routes of drug administration. , 2008, Journal of pharmaceutical sciences.

[109]  M. Prato,et al.  Functionalized carbon nanotubes in drug design and discovery. , 2008, Accounts of chemical research.

[110]  J. Fréchet,et al.  Dendrimers and dendritic polymers in drug delivery. , 2005, Drug discovery today.

[111]  Robert Gurny,et al.  Biodegradable polymers for the controlled release of ocular drugs , 1998 .

[112]  A. Frankel,et al.  HIV-1: fifteen proteins and an RNA. , 1998, Annual review of biochemistry.

[113]  J. San roma´n,et al.  Functionalization of poly(l-lactide) macromonomers by ring-opening polymerization of l-lactide initiated with hydroxyethyl methacrylate-aluminium alkoxides , 1995 .

[114]  Robert Gurny,et al.  Drug loaded poly(lactic acid) nanoparticles produced by a reversible salting-out process : purification of an injectable dosage form , 1993 .